Cleo Diagnostics (ASX:COV) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Cleo Diagnostics's annualized Gross Profit for the quarter that ended in Dec. 2023 was A$0.00 Mil. Cleo Diagnostics's average Total Assets over the quarter that ended in Dec. 2023 was A$5.91 Mil. Therefore, Cleo Diagnostics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.

Cleo Diagnostics Gross-Profit-to-Asset % Historical Data

The historical data trend for Cleo Diagnostics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Gross-Profit-to-Asset % Chart

Cleo Diagnostics Annual Data

Trend

Jun23

Gross-Profit-to-Asset %

Cleo Diagnostics Semi-Annual Data
	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	-	-	-

Competitive Comparison of Cleo Diagnostics's Gross-Profit-to-Asset %

For the Medical Devices subindustry, Cleo Diagnostics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cleo Diagnostics's Gross-Profit-to-Asset % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Gross-Profit-to-Asset % falls into.

Cleo Diagnostics Gross-Profit-to-Asset % Calculation

Cleo Diagnostics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2023 )	/	( (Total Assets (A: . 20 )	+	Total Assets (A: Jun. 2023 ))	/ count )
	=		/	( (	+	)	/ )
	=		/
	=	%

Cleo Diagnostics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (1.077	+	10.739)	/ 2 )
	=	0	/	5.908
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Cleo Diagnostics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cleo Diagnostics (ASX:COV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000

Website

https://www.cleodx.com

Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines